| 日 | 月 | 火 | 水 | 木 | 金 | 土 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 |
< memo Within Our Reac... | メイン | PMR治療におけるレミケードの有用性(G... >
NY Times
By ANDREW POLLACK
Published: July 14, 2007
高額医薬品に対する、Pay-for-performance pricing/risk-sharing/satisfaction guranteed導入の試み（英国）
Johnson & Johnson has proposed that Britain’s national health service pay for the cancer drug Velcade, but only for people who benefit from the medicine, which can cost $48,000 a patient. The company would refund any money spent on patients whose tumors do not shrink sufficiently after a trial treatment.
固定リンク | コメント (0) | トラックバック (0)
コメント
コメントはまだありません。コメントを書く